retractions in bibtex entries, lol my solution
Mike Marchywka
marchywka at hotmail.com
Sun Dec 11 02:26:38 CET 2022
On Sat, Dec 10, 2022 at 06:31:43PM -0500, Mike Marchywka wrote:
> On Sat, Dec 10, 2022 at 09:14:05PM +0000, Schneider, Thomas (NIH/NCI) [E] wrote:
> > Mike:
> >
[...]
> >
> > I use my own tcsh script to convert PubMed entries into bibtex format.
> > It uses a Pascal program - ancient but reliable tools (like LaTeX!).
> >
> > https://alum.mit.edu/www/toms/delila/medlinebib.html
> >
[...]
> >
> > https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=35815265&rettype=medline&retmode=text
>
[...]
> >
> Thanks. Actually this is what I should try first but I checked the
> file and wget could not find the server ?!?!?!?. I have noticed
> several times lately that the pubmed links seem to be slow
> and go to the fetchpage handlers instead of using eutils but I
> don't usually check. WTH it would have DNS problems is beyond me-
> in the past the PMCID was not found on very recent articles
> so I assumed it may just be flakey at the NCBI.
>
[...]
I think this fixed it, adding the 8.8.8.8 by hand also speeded up
one slow page that may be shadow banned by ISP lol.
# Dynamic resolv.conf(5) file for glibc resolver(3) generated by resolvconf(8)
# DO NOT EDIT THIS FILE BY HAND -- YOUR CHANGES WILL BE OVERWRITTEN
nameserver 8.8.8.8
nameserver 127.0.1.1
search gha.chartermi.net
[...]
> >
> > So you can use that to identify retracted publications - no unreliable
> > html scraping needed!!
> >
> > Tom
> >
> > Thomas D. Schneider, Ph.D.
> > Senior Investigator
> > National Institutes of Health
> > National Cancer Institute
> > Center for Cancer Research
> > RNA Biology Laboratory
> > Biological Information Theory Group
> > Frederick, Maryland 21702-1201
> > schneidt at mail.nih.gov
> > alum.mit.edu/www/toms
> > https://alum.mit.edu/www/toms
> >
> >
>
> > PMID- 35815265
> > OWN - NLM
> > STAT- PubMed-not-MEDLINE
> > LR - 20221209
> > IS - 1741-427X (Print)
> > IS - 1741-4288 (Electronic)
> > IS - 1741-427X (Linking)
> > VI - 2022
> > DP - 2022
> > TI - Effects of Tenofovir Combined with Recombinant Human Interferon alpha-2b on Negative
> > Conversion Rate, Liver Function, Immune Status, and Drug Safety in Patients with
> > Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
> > PG - 1889628
> > LID - 10.1155/2022/1889628 [doi]
> > LID - 1889628
> > AB - OBJECTIVE: To systematically evaluate the clinical value of tenofovir combined
> > with recombinant human interferon alpha-2b in the treatment of chronic hepatitis B
> > and to provide evidence-based medicine for its popularization and use. METHODS:
> > The randomized controlled trials (RCTs) of tenofovir combined with recombinant
> > human interferon alpha-2b in the online database of PubMed, EMBASE, ScienceDirect,
> > Cochrane Library, China knowledge Network (CNKI), China VIP database, Wanfang
> > database, and China Biomedical Literature Database (CBM) were searched. The data
> > included in this study were extracted by two independent researchers. After
> > extracting the data of the study, the Cochrane manual 5.1.0 standard was used to
> > evaluate the bias risk of all the literature included in this study. RevMan5.4
> > statistical software was used to analyze the collected data by meta. RESULTS:
> > Entecavir combined with recombinant human interferon alpha-2b can inhibit the
> > activity of HBV polymerase and improve the inflammatory response of the liver.
> > Recombinant human interferon alpha-2b can regulate immune function by inducing T cell
> > differentiation and maturation and enhancing the production of cytokines. The
> > systematic evaluation showed that entecavir combined with recombinant human
> > interferon alpha-2b had higher serum HBeAg negative conversion rate, higher drug
> > safety compared with entecavir alone, and improved liver function and immune
> > status. CONCLUSION: Tenofovir combined with recombinant human interferon alpha-2b
> > has a high serum HBeAg negative rate and safety profile for the treatment of
> > chronic hepatitis B. The combination treatment can improve liver function and
> > immune status in patients, but more studies with higher methodological quality
> > and longer duration of intervention are needed for further validation.
> > CI - Copyright (c) 2022 Hui Zhang et al.
> > FAU - Zhang, Hui
> > AU - Zhang H
> > AD - The Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou
> > 225300, China.
> > FAU - Xian, Jianchun
> > AU - Xian J
> > AD - The Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou
> > 225300, China.
> > FAU - Li, Yang
> > AU - Li Y
> > AD - The Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou
> > 225300, China.
> > FAU - Xiao, Li
> > AU - Xiao L
> > AD - The Medical Department of Hepatology, Jiangsu Taizhou People's Hospital, Taizhou
> > 225300, China.
> > FAU - Wang, Lu
> > AU - Wang L
> > AUID- ORCID: 0000-0002-1266-7916
> > AD - The Medical Department of Neurology, Jiangsu Taizhou People's Hospital, Taizhou
> > 225300, China.
> > LA - eng
> > PT - Journal Article
> > PT - Retracted Publication
> > DEP - 20220630
> > PL - United States
> > TA - Evid Based Complement Alternat Med
> > JT - Evidence-based complementary and alternative medicine : eCAM
> > JID - 101215021
> > RIN - Evid Based Complement Alternat Med. 2022 Nov 29;2022:9791408. PMID: 36482933
> > PMC - PMC9262527
> > COIS- The authors declare that they have no conflicts of interest.
> > EDAT- 2022/07/12 06:00
> > MHDA- 2022/07/12 06:01
> > CRDT- 2022/07/11 04:30
> > PHST- 2022/05/07 00:00 [received]
> > PHST- 2022/05/25 00:00 [revised]
> > PHST- 2022/05/29 00:00 [accepted]
> > PHST- 2022/07/11 04:30 [entrez]
> > PHST- 2022/07/12 06:00 [pubmed]
> > PHST- 2022/07/12 06:01 [medline]
> > AID - 10.1155/2022/1889628 [doi]
> > PST - epublish
> > SO - Evid Based Complement Alternat Med. 2022 Jun 30;2022:1889628. doi:
> > 10.1155/2022/1889628. eCollection 2022.
>
>
> --
>
> mike marchywka
> 306 charles cox
> canton GA 30115
> USA, Earth
> marchywka at hotmail.com
> 404-788-1216
> ORCID: 0000-0001-9237-455X
>
--
mike marchywka
306 charles cox
canton GA 30115
USA, Earth
marchywka at hotmail.com
404-788-1216
ORCID: 0000-0001-9237-455X
More information about the texhax
mailing list.